Novartis has said it has partnered leading healthcare company USV to market its product Galvus in India.
The anti-diabetic drug a DPP-IV inhibitor and is an oral agent for type two diabetes.
Unlike insulin therapy, the product works by enhancing the body's ability to lower blood sugar levels.
Commenting on the collaboration, Rajit Shahani, vice-chairman and managing director of Novartis, said: "The diabetes market in India is large and Novartis looks to have a sizeable share of that segment."
He added: "We are thus looking at several opportunities to make that happen."
Last week, Novartis announced it was working on several medicines and drugs, in an attempt to combine them into a single pill.
The announcement followed the company's expected loss of revenue when the patent for its Diovan expires in four years.
The combination pill will see the company's heart medicine Rasilez mixed with Diovan, with the hope for it to be filed for US approval by the end of the year.
Novartis currently employs 100,000 people and operates in 140 countries.
Based in Basel, Switzerland, it increased research and development investments by more than 20 per cent to $6.4 billion (4.3 billion pounds) over the course of 2007.See all the latest jobs in Pharmaceutical